Search Clinical Trials
Sponsor Condition of Interest |
---|
A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to...
Merck Sharp & Dohme LLC
Ulcerative Colitis
The purpose of this protocol is to evaluate the efficacy and safety of tulisokibart in
participants with moderately to severely active ulcerative colitis. Study 1's primary
hypotheses are that at least 1 tulisokibart dose level is superior to Placebo in the
proportion of participants achieving clinical... expand
The purpose of this protocol is to evaluate the efficacy and safety of tulisokibart in participants with moderately to severely active ulcerative colitis. Study 1's primary hypotheses are that at least 1 tulisokibart dose level is superior to Placebo in the proportion of participants achieving clinical remission per Modified Mayo Score at Week 12, and that at least 1 tulisokibart dose level is superior to Placebo in the proportion of participants achieving clinical remission per Modified Mayo Score at week 52. Study 2's primary hypothesis is that at least 1 tulisokibart dose level is superior to Placebo in the proportion of participants achieving clinical remission per Modified Mayo Score at Week 12. Type: Interventional Start Date: Oct 2023 |
A Study to Assess Adverse Events of Intravenously (IV) Infused ABBV-383 in Adult Participants With Relapsed...
TeneoOne Inc.
Multiple Myeloma
Multiple Myeloma (MM) is a cancer of the blood's plasma cells ( blood cell). The cancer
is typically found in the bones and bone marrow (the spongy tissue inside of the bones)
and can cause bone pain, fractures, infections, weaker bones, and kidney failure.
Treatments are available, but MM can come... expand
Multiple Myeloma (MM) is a cancer of the blood's plasma cells ( blood cell). The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, and kidney failure. Treatments are available, but MM can come back (relapsed) or may not get better (refractory) with treatment. This is a study to determine adverse events and change in disease symptoms of ABBV-383 in adult participants with relapsed/refractory (R/R) MM. ABBV-383 is an investigational drug being developed for the treatment of R/R Multiple Myeloma (MM). This study is broken into 3 Arms; Arm A (Parts 1 and 2), Arm B and Arm C. Arm A includes 2 parts: step-up dose optimization (Part 1) and dose expansion (Part 2). In Part 1, different level of step-up doses are tested followed by the target dose of ABBV-383. In Part 2, the step-up dose identified in Part 1 (Dose A) will be used followed by the target dose A of ABBV-383. In Arm B a flat dose of ABBV-383 will be tested. "In Arm C, the step-up dose identified in Arm A will be used followed by the target dose of ABBV-383 to investigate outpatient administration of ABBV-383. Around 180 adult participants with relapsed/refractory multiple myeloma will be enrolled at approximately 40 sites across the world. Participants will receive ABBV-383 as an infusion into the vein in 28 day cycles for approximately 3 years. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and questionnaires. Type: Interventional Start Date: Mar 2023 |
A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced...
Janssen Research & Development, LLC
Prostatic Neoplasms
Adenocarcinoma
The purpose of this study is to determine the recommended Phase 2 dose(s) (RP2D[s]) of
JNJ-69086420 in Part 1 (Dose Escalation) and to determine safety and preliminary signs of
clinical activity at the RP2D(s) in Part 2 (Dose Expansion). expand
The purpose of this study is to determine the recommended Phase 2 dose(s) (RP2D[s]) of JNJ-69086420 in Part 1 (Dose Escalation) and to determine safety and preliminary signs of clinical activity at the RP2D(s) in Part 2 (Dose Expansion). Type: Interventional Start Date: Nov 2020 |
A Long Term, Post-marketing Study of Immune Response in Patients Receiving Palynziq Treatment for PKU...
BioMarin Pharmaceutical
Phenylketonuria (PKU)
This is a 10-year multi-center, prospective, longitudinal, single arm study evaluating
immunologic, inflammatory and laboratory parameters associated with long-term Palynziq
treatment in subjects with phenylketonuria (PKU) in the United States (US). Subjects in
the US for whom a clinical decision... expand
This is a 10-year multi-center, prospective, longitudinal, single arm study evaluating immunologic, inflammatory and laboratory parameters associated with long-term Palynziq treatment in subjects with phenylketonuria (PKU) in the United States (US). Subjects in the US for whom a clinical decision has been made that they will receive pegvaliase to treat their PKU within 30 days following the date of enrollment in Study 165-501 (incident-users) or who have previously started treatment with pegvaliase at the date of enrollment in Study 165-501 (prevalent-users) are eligible for participation in Study 165-503. Type: Observational Start Date: Jan 2024 |
Strategies for Implementing a Postpartum Lifestyle Intervention in WIC Clinics
Tulane University
Obesity
Gestational Diabetes
Lifestyle, Healthy
Glucose Intolerance During Pregnancy
PreDiabetes
The primary objective of the STRIVE study is to compare two implementation strategies for
Diabetes Prevention Program delivery: an in-person health coach strategy (standard 24
in-person sessions at WIC clinics) vs. a multifaceted technology-assisted health coach
implementation strategy (12 in-person... expand
The primary objective of the STRIVE study is to compare two implementation strategies for Diabetes Prevention Program delivery: an in-person health coach strategy (standard 24 in-person sessions at WIC clinics) vs. a multifaceted technology-assisted health coach implementation strategy (12 in-person sessions at WIC clinics supplemented by technology support) on implementation and health-related outcomes in postpartum women. Type: Interventional Start Date: Dec 2023 |
Baseline Atrial Fibrosis Predicts Risk for Post-operative Atrial Fibrillation in Patients Undergoing...
Tulane University
Atrial Fibrillation
Atrial Arrhythmia
Atrial Flutter
Atrial Tachycardia
The study aims to evaluate and compare the incidence of atrial arrhythmias (including
Post-Operative Atrial Fibrillation (POAF), atrial flutter, and atrial tachycardia)
stratified by baseline Utah fibrosis stages and overall fibrosis (%) of the left atrial
wall area. The investigators hypothesize... expand
The study aims to evaluate and compare the incidence of atrial arrhythmias (including Post-Operative Atrial Fibrillation (POAF), atrial flutter, and atrial tachycardia) stratified by baseline Utah fibrosis stages and overall fibrosis (%) of the left atrial wall area. The investigators hypothesize that patients with a higher baseline Utah fibrosis staging will experience a higher incidence of POAF. The study also aims to evaluate and compare the in-hospital mortality, length-of-stay (LOS), complication rates (strokes, pneumonia, respiratory failure etc.) of the different Utah fibrosis stage cohorts. Perform cost analysis and compare between patients with POAF and patients without POAF. The investigators hypothesize that patients experiencing POAF will have a higher mortality rate, longer LOS, greater complications, and therefore, additional hospital costs. Type: Observational Start Date: Nov 2021 |
Advanced Cardiac Imaging To Predict Embolic Stroke On Brain MRI: A Pilot Study
Tulane University
Atrial Fibrillation
Stroke
Stroke, Cardiovascular
Vascular Cognitive Impairment
Strokes Thrombotic
Demonstrating the pathophysiological link between Left Atrial (LA) and Left Atrial
Appendage (LAA) pathology and embolic strokes in non-Atrial Fibrillation (AF) individuals
represents a major advance in stroke prevention strategies. Instead of relying on
non-specific criteria for stroke risk assessment,... expand
Demonstrating the pathophysiological link between Left Atrial (LA) and Left Atrial Appendage (LAA) pathology and embolic strokes in non-Atrial Fibrillation (AF) individuals represents a major advance in stroke prevention strategies. Instead of relying on non-specific criteria for stroke risk assessment, the investigators propose to identify individuals with high-risk of embolic stroke using imaging criteria that reflect the underlying pathophysiology of embolic stroke of cardiac origin. the investigators can therefore lay the groundwork for future anticoagulation strategies for stroke prevention beyond AF. Type: Interventional Start Date: Apr 2021 |
Emicizumab in Patients with Acquired Hemophilia a
University of Washington
Acquired Hemophilia a
This is a phase II multicenter open-label, single-arm prospective study to evaluate the
efficacy of prophylactic emicizumab administered on a scheduled basis to prevent bleeds
in patients with acquired hemophilia A (AHA). expand
This is a phase II multicenter open-label, single-arm prospective study to evaluate the efficacy of prophylactic emicizumab administered on a scheduled basis to prevent bleeds in patients with acquired hemophilia A (AHA). Type: Interventional Start Date: Aug 2022 |
Lupus Education Alliance Program
Tulane University
Systemic Lupus Erythematosus
COVID-19
The purpose of this study is to evaluate the evaluate the effect of education-only vs.
navigation interventions on COVID-19 testing and vaccination for people with systemic
lupus erythematosus. expand
The purpose of this study is to evaluate the evaluate the effect of education-only vs. navigation interventions on COVID-19 testing and vaccination for people with systemic lupus erythematosus. Type: Interventional Start Date: Nov 2023 |
Blood Pressure Lowering Strategies to Eliminate Hypertension Disparities (BLESSED)
Tulane University
Hypertension
The burden of hypertension and related cardiovascular diseases, stroke, and end-stage
kidney disease is disproportionately high in Black populations, especially in the South.
The Blood Pressure Lowering Strategies to Eliminate Hypertension Disparities (BLESSED)
cluster randomized trial aims to test... expand
The burden of hypertension and related cardiovascular diseases, stroke, and end-stage kidney disease is disproportionately high in Black populations, especially in the South. The Blood Pressure Lowering Strategies to Eliminate Hypertension Disparities (BLESSED) cluster randomized trial aims to test the effectiveness, implementation, and sustainability of a community health worker (CHW)-led multifaceted intervention compared to enhanced usual care for hypertension control in Black communities. In the BLESSED trial, the investigators plan to recruit 1,176 Black adults with hypertension (approximately 28 per church) from 42 churches in the Greater New Orleans area. The multifaceted intervention will last for 18 months, followed by a post-intervention follow-up visit at 24 months. The BLESSED trial aims to generate evidence regarding the effectiveness, implementation, and sustainability of this CHW-led church-based multifaceted intervention in eliminating hypertension disparities in the United States (US) general population. Type: Interventional Start Date: Nov 2023 |
Evaluation of the Efficacy and Safety of DMR Using the Revita® in Subjects With Inadequately Controlled...
Fractyl Health Inc.
Type 2 Diabetes
The Revita® system is being investigated to assess the efficacy of DMR versus Sham on
improvement in Glycemic, Hepatic and Cardiovascular endpoints for patients with Type 2
Diabetes who are inadequately controlled on one or more glucose lowering agents. The
purpose of this study is to demonstrate... expand
The Revita® system is being investigated to assess the efficacy of DMR versus Sham on improvement in Glycemic, Hepatic and Cardiovascular endpoints for patients with Type 2 Diabetes who are inadequately controlled on one or more glucose lowering agents. The purpose of this study is to demonstrate the efficacy and safety of the Fractyl DMR Procedure using the Revita® System compared to a sham. Subjects randomized to the DMR procedure will be followed per protocol till 48 weeks post treatment. Subjects in the Sham treatment arm will be offered cross over to receive the DMR treatment at 48 weeks and will be followed per protocol for 48 weeks post treatment. Type: Interventional Start Date: Mar 2021 |
M-O-M-S on the Bayou: Implementation of an Intervention for Mental Health in Pregnancy
Tulane University
Anxiety
Depression
Disasters have negative effects in the short term (physical trauma, adverse environmental
exposures, and unstable housing) and the long term (relocation, changes in family
functioning, and negative economic effects), which interact with social determinants to
worsen health among the most vulnerable... expand
Disasters have negative effects in the short term (physical trauma, adverse environmental exposures, and unstable housing) and the long term (relocation, changes in family functioning, and negative economic effects), which interact with social determinants to worsen health among the most vulnerable women, infants, and communities. Trauma and severe stress are directly linked to pregnancy complications, and raise blood pressure during pregnancy, alter stress hormones, and increase vulnerability to infection, all of which predispose to reduced fetal growth and preterm birth. Disasters also worsen mental health, and depression during pregnancy and postpartum, for instance, is associated with worse physical health during pregnancy, maternal impairment, poorer quality parenting, negative child behavior, and poorer infant cognitive development.The goal of this intervention is to improve mental health in pregnant women living in a disaster-affected region. The main questions this intervention aims to answer are: - Assess the implementation outcomes (acceptability, adaptation, adoption, feasibility, fidelity, and sustainability) of a pilot intervention in a disaster recovery environment. - Assess the effectiveness of the M-O-M-S pilot intervention in a disaster recovery environment. The study will recruit pregnant women in areas that have experienced a natural disaster. Women will be recruited in early pregnancy and attend a series of classes on the cognitive and relationship changes of pregnancy and motherhood, and mental preparation for labor, led by a "mentor," a mother who has experienced pregnancy, labor, and motherhood. Type: Interventional Start Date: Nov 2023 |
Collection of SARS CoV-2 (COVID-19) Virus Secretions and Serum for Countermeasure Development
Tulane University
Covid19
Collection of SARS-COV-2 Secretions and Serum for Countermeasure Development (aka
ClinSeqSer) is an observational study to understand natural history of SARS-COV-2
infections among special populations and characterise post-covid morbidity through immune
response, virus genome sequencing, cytokine... expand
Collection of SARS-COV-2 Secretions and Serum for Countermeasure Development (aka ClinSeqSer) is an observational study to understand natural history of SARS-COV-2 infections among special populations and characterise post-covid morbidity through immune response, virus genome sequencing, cytokine response, and virus shedding. Given the descriptions of infection course of patients over the outbreak of 2003 (SARS-Cov01) and since January 2019 in China and Europe, and now worldwide: 1. Acutely infected patients shed virus that could be of major interest to characterize (viral quantification, characterization of virus shedding -of infective and of non-infective virus) the former reflecting/predictive of severity of disease and the latter reflecting extent/source of contagiosity. 2. Convalescent infected patients develop a specific anti-virus antibody response that is (likely) protective and therefore suits the preliminary requirement for the potential benefits of the convalescent patient plasma therapeutic infusion approach. In addition, long term effects of COVID-19 commonly known as long-haulers remains clinically unclear. Thousands of patients have now been diagnosed with COVID-19 in Louisiana (444,000 cases, 10,122 deaths, 2.2% mortality in Louisiana (LA), as of March 2021), and numerous patients are now also complaining of post-acute sequelae of SARS-CoV-2 (PASC). The investigators want to further clarify questions surrounding rational confinement duration and therapeutic approach by collecting plasma of convalescent patients to identify optimal antibody titer by ELISA, specificity of naturally occurring inflammatory (protein/antibody and RNA) response, and possibly test in vitro antibody neutralization activity. Type: Observational Start Date: Mar 2020 |
Prospective Study of Pregnancy in Women With Cystic Fibrosis
Amalia Magaret
Pregnancy Related
Cystic Fibrosis
In this study, the investigators aim to evaluate changes in lung function in women with
cystic fibrosis (CF) during pregnancy and for 2 years after pregnancy based on exposure
to highly effective cystic fibrosis transmembrane conductance regulator (CFTR)
modulators. expand
In this study, the investigators aim to evaluate changes in lung function in women with cystic fibrosis (CF) during pregnancy and for 2 years after pregnancy based on exposure to highly effective cystic fibrosis transmembrane conductance regulator (CFTR) modulators. Type: Observational Start Date: Sep 2021 |
Adolescent Master Protocol for Participants 18 Years of Age and Older (AMP Up)
Harvard School of Public Health (HSPH)
HIV/AIDS
This is a prospective cohort study designed to define the impact of HIV infection and
antiretroviral therapy (ART) on young adults with perinatal HIV infection (YAPHIV) as
they transition into adulthood. A group of of perinatally exposed but uninfected young
adults from a similar sociodemographic... expand
This is a prospective cohort study designed to define the impact of HIV infection and antiretroviral therapy (ART) on young adults with perinatal HIV infection (YAPHIV) as they transition into adulthood. A group of of perinatally exposed but uninfected young adults from a similar sociodemographic background and age distribution will be enrolled for comparison. Type: Observational Start Date: Apr 2014 |
A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients With PV
PharmaEssentia
Polycythemia Vera
A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients with PV expand
A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients with PV Type: Interventional Start Date: Oct 2022 |
A Follow-up Study to Test Long-term Treatment With BI 1015550 in People With Pulmonary Fibrosis Who Took...
Boehringer Ingelheim
Idiopathic Pulmonary Fibrosis
Progressive Pulmonary Fibrosis
This study is open to people with idiopathic pulmonary fibrosis (IPF) or progressive
pulmonary fibrosis (PPF). They can only take part if they have completed treatment in a
previous study with a medicine called BI 1015550 (study 1305-0014 or 1305-0023).
The goal of this study is to find out how... expand
This study is open to people with idiopathic pulmonary fibrosis (IPF) or progressive pulmonary fibrosis (PPF). They can only take part if they have completed treatment in a previous study with a medicine called BI 1015550 (study 1305-0014 or 1305-0023). The goal of this study is to find out how well people with pulmonary fibrosis tolerate longterm treatment with BI 1015550. The study also tests whether BI 1015550 improves lung function and prolongs the time until symptoms get worse, participants need to go to the hospital, or die. Every participant takes BI 1015550 as tablets for up to 1 year and 10 months. The participants may also continue their regular treatment for pulmonary fibrosis during the study. Participants visit their doctors regularly. During these visits, the doctors collect information on any health problems of the participants. Participants also regularly do lung function tests. Type: Interventional Start Date: Jul 2024 |
Observational Study for Patients at Risk for Chronic Graft-Versus-Host Disease
Incyte Corporation
cGVHD
The purpose of this prospective observational study is to collect data from participants
who have recently had an allogenic Stem Cell Transplant(alloSCT) and are at risk of
Chronic Graft Versus Host Disease(cGVHD) expand
The purpose of this prospective observational study is to collect data from participants who have recently had an allogenic Stem Cell Transplant(alloSCT) and are at risk of Chronic Graft Versus Host Disease(cGVHD) Type: Observational Start Date: Aug 2023 |
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib...
Celgene
Relapsed or Refractory Multiple Myeloma
The purpose of this study is to compare the efficacy and safety of mezigdomide
(CC-92480), bortezomib and dexamethasone (MeziVd) versus pomalidomide, bortezomib and
dexamethasone (PVd) in participants with relapsed or refractory multiple myeloma (RRMM)
who received between 1 to 3 prior lines of therapy... expand
The purpose of this study is to compare the efficacy and safety of mezigdomide (CC-92480), bortezomib and dexamethasone (MeziVd) versus pomalidomide, bortezomib and dexamethasone (PVd) in participants with relapsed or refractory multiple myeloma (RRMM) who received between 1 to 3 prior lines of therapy and who have had prior lenalidomide exposure. Type: Interventional Start Date: Sep 2022 |
Trial on Efficacy and Safety of Pritelivir Tablets for Treatment of Acyclovir-resistant Mucocutaneous...
AiCuris Anti-infective Cures AG
HSV Infection
Randomized, open-label, multi-center, comparative trial to assess the efficacy and safety
in immunocompromised subjects with acyclovir resistant or acyclovir susceptible
mucocutaneous HSV infection, treated with pritelivir 100 mg once daily (following a
loading dose of 400 mg as first dose to rapidly... expand
Randomized, open-label, multi-center, comparative trial to assess the efficacy and safety in immunocompromised subjects with acyclovir resistant or acyclovir susceptible mucocutaneous HSV infection, treated with pritelivir 100 mg once daily (following a loading dose of 400 mg as first dose to rapidly reach steady-state plasma concentration) or investigators choice, which can be either foscarnet 40 mg/kg every 8 hours or 60 mg/kg every 12 hours, or Cidofovir iv 5 mg/kg body weight given once weekly, or Cidofovir 1% or 3% topical applied 2 to 4 times daily, or Imiquimod 5% topical 3 times per week) (provided the drug is nationally approved). Type: Interventional Start Date: May 2017 |
Randomized Study of the pdSTIM™ System (Phrenic Nerve to Diaphragm STIMulation) in Failure to Wean Mechanically...
Stimdia Medical Inc.
Ventilator Induced Diaphragm Dysfunction
This prospective, multi-center, randomized, controlled clinical trial is being conducted
to evaluate the safety and efficacy of the pdSTIM System to facilitate weaning from
mechanical ventilation through phrenic nerve stimulation. Potential subjects who are on
mechanical ventilation for at least four... expand
This prospective, multi-center, randomized, controlled clinical trial is being conducted to evaluate the safety and efficacy of the pdSTIM System to facilitate weaning from mechanical ventilation through phrenic nerve stimulation. Potential subjects who are on mechanical ventilation for at least four days and have failed at least one weaning attempt will be considered for the study. Those enrolled will be randomized in a 1:1 manner between the treatment group that is standard of care with the pdSTIM System and a Control group, which is standard of care alone. The primary endpoints focus on time to weaning and serious adverse event rates between the Treatment and Control groups. Type: Interventional Start Date: Sep 2023 |
Efficacy and Safety of Lorundrostat in Subjects with Uncontrolled and Resistant Hypertension
Mineralys Therapeutics Inc.
Hypertension
This is a Phase 3 trial to evaluate the BP-lowering effect of lorundrostat (an
aldosterone synthase inhibitor) in subjects with uncontrolled and resistant hypertension
taking between 2 and 5 anti-hypertensive (AHT) medications. expand
This is a Phase 3 trial to evaluate the BP-lowering effect of lorundrostat (an aldosterone synthase inhibitor) in subjects with uncontrolled and resistant hypertension taking between 2 and 5 anti-hypertensive (AHT) medications. Type: Interventional Start Date: Nov 2023 |
Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Prospective Outcomes Registry
Duke University
Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease
The Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) Registry started
recruiting in 2014 with the objective of studying Idiopathic Pulmonary Fibrosis. In 2018,
the registry expanded to include recruitment of participants with other chronic fibrosing
interstitial lung diseases (ILDs) with... expand
The Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) Registry started recruiting in 2014 with the objective of studying Idiopathic Pulmonary Fibrosis. In 2018, the registry expanded to include recruitment of participants with other chronic fibrosing interstitial lung diseases (ILDs) with progressive phenotype also referred to as progressive fibrosing interstitial lung diseases in the Chronic Fibrosis Interstitial Lung Disease with Progressive Phenotype (ILD-PRO) Registry. When the third phase of the registry begins, the IPF-PRO registry will enroll additional patients with idiopathic pulmonary fibrosis. This IPF-PRO registry is a prospective registry that will collect information regarding the natural history, health care interactions, participant reported questionnaire data to assess quality of life, and the methods of treatment of participants with a diagnosis of idiopathic pulmonary fibrosis (IPF) or of another chronic fibrosing interstitial lung disease (ILD) with progressive phenotype established at the enrolling centers. In addition, blood samples and chest image studies will be collected and banked for future research projects. Type: Observational [Patient Registry] Start Date: Jun 2014 |
Implementation of Multifaceted Patient-Centered Treatment Strategies for Intensive Blood Pressure Control...
Tulane University
Hypertension
Cognitive Decline
The study will test a multifaceted strategy for implementing an intensive blood pressure
intervention protocol targeting systolic BP <120 mmHg on cognitive decline in racial
minority and low-income hypertensive patients in primary care. The proposed study will
generate urgently needed data on effective,... expand
The study will test a multifaceted strategy for implementing an intensive blood pressure intervention protocol targeting systolic BP <120 mmHg on cognitive decline in racial minority and low-income hypertensive patients in primary care. The proposed study will generate urgently needed data on effective, adoptable, and equitable intervention strategies to reduce blood pressure-related cognitive decline in low- income and minority populations. If proven effective, the implementation strategy for intensive blood pressure reduction could be adapted and scaled up in diverse primary care settings to prevent cognitive decline and clinical dementia. Type: Interventional Start Date: Oct 2019 |
Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib)...
National Cancer Institute (NCI)
Advanced Renal Cell Carcinoma
Chromophobe Renal Cell Carcinoma
Clear Cell Renal Cell Carcinoma
Collecting Duct Carcinoma
Kidney Medullary Carcinoma
This phase II trial studies whether adding radium-223 dichloride to the usual treatment,
cabozantinib, improves outcomes in patients with renal cell cancer that has spread to the
bone. Radioactive drugs such as radium-223 dichloride may directly target radiation to
cancer cells and minimize harm to... expand
This phase II trial studies whether adding radium-223 dichloride to the usual treatment, cabozantinib, improves outcomes in patients with renal cell cancer that has spread to the bone. Radioactive drugs such as radium-223 dichloride may directly target radiation to cancer cells and minimize harm to normal cells. Cabozantinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving radium-223 dichloride and cabozantinib may help lessen the pain and symptoms from renal cell cancer that has spread to the bone, compared to cabozantinib alone. Type: Interventional Start Date: Jul 2020 |
- Previous
- Next